English
简体中文
Total: £ 56.28
Published Date: 2025-06-25 | Pages: 127 | Tables: 124 | Medical Care
In 2024, the global market size of PD-L1 Biomarker Testing was estimated to be worth US$ 2815 million and is forecast to reach approximately US$ 27020 million by 2031 with a CAGR of 38.7% during the forecast period 2025-2031.
PD-L1 Biomarker Testing measures the amount of PDL1 on cancer cells. PDL1 is a protein that helps keep immune cells from attacking nonharmful cells in the body. Normally, the immune system fights foreign substances like viruses and bacteria, and not your own healthy cells. Some cancer cells have high amounts of PDL1. This allows the cancer cells to "trick" the immune system, and avoid being attacked as foreign, harmful substances.
Current PD-L1 testing is based on immunohistochemistry (IHC) methods. Immunohistochemistry (IHC) is the process whereby antibodies are used to detect proteins (antigens) in cells within a tissue section (for instance liver, pancreas or the heart).
PD-L1 is a ligand that binds to PD-1 (programmed cell death-1), expressed on activated T cells, to evade anti-tumor responses. PD-L1 plays a role in inhibiting T cell activation and proliferation and has emerged as an important target in cancer treatment. PD-L1 protein detection by immunohistochemistry (IHC) testing is widely used as a predictive biomarker assay for anti–PD-1/PD-L1 therapies.
PDL1 testing is used to find out if you have a cancer that may benefit from immunotherapy.
The classification of PD-L1 Biomarker Testing includes PD-L1 (22C3), PD-L1 (28-8), PD-L1 (SP142), PD-L1 (SP263) and Other, and the revenue proportion of PD-L1 (22C3) in 2019 is about 21.68%.
PD-L1 Biomarker Testing is widely used in Hospital and Diagnostic Laboratories. The most proportion of PD-L1 Biomarker Testing is Hospital, and the proportion in 2019 is about 52.7%.
North Americas is the largest consumption place, with a consumption market share nearly 55.63% in 2019. Following North Americas, Europe is the second largest consumption place with the consumption market share of 26.7%.
Report Scope
This report aims to provide a comprehensive presentation of the global market for PD-L1 Biomarker Testing, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding PD-L1 Biomarker Testing.
The PD-L1 Biomarker Testing market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global PD-L1 Biomarker Testing market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the PD-L1 Biomarker Testing companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, product type, application, and regions.
Market Segmentation
By Company
Agilent Technologies
Roche
Merck
Bristol-Myers Squibb
AstraZeneca
Ono Pharmaceutical
Regeneron
Innovent
Hengrui Medicine
Junshi Biosciences
Segment by Type
PD-L1 (22C3)
PD-L1(28-8)
PD-L1 (SP142)
PD-L1 (SP263)
Other
Segment by Application
Hospital
Diagnostic Center
Others
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
India
Southeast Asia
Australia
Rest of Asia-Pacific
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on.
Chapter 2: Revenue of PD-L1 Biomarker Testing in global and regional level.
Chapter 3: Detailed analysis of PD-L1 Biomarker Testing company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, PD-L1 Biomarker Testing revenue, gross margin, and recent development, etc.
Chapter 5: Provides the analysis of various market segments by Type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 6: Provides the analysis of various market segments by Application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 7: North America (US & Canada) by Type, by Application and by country, revenue for each segment.
Chapter 8: Europe by Type, by Application and by country, revenue for each segment.
Chapter 9: Asia Pacific by Type, by Application and by region, revenue for each segment.
Chapter 10: Latin America by Type, by Application and by country, revenue for each segment.
Chapter 11: Middle East and Africa, by Type, by Application and by country, revenue for each segment.
Chapter 12: Analysis of industrial chain, sales channel, key raw materials, distributors, and customers.
Chapter 13: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 14: Research Findings and Conclusion
Research Methodology
The research methodology employed has been subjected by numerous procedures in order to guarantee the quality and accuracy of the data contained within the reports. The analysts are employed full-time and received more than six months training to satisfy the standard of our company. Our methodology can be divided into five stages:
★Stage 1 SECONDARY RESEARCH
The research team first collaborates with magazines, trade associations and administrative departments in the research field. The information provided by our internal documentation service is helpful for our further research. Our team has a wealth of experience and knowledge, and can effectively extract accurate information from existing resources.
★Stage 2 PRIMARY RESEARCH:INTERVIEWS WITH TRADE SOURCES
After the first stage, the research team conducts a large number of face-to-face or telephone interviews with representative companies working in the research field. Analysts are trying to have an opportunity to talk to leading companies and small companies in the field. Upstream suppliers, manufacturers, distributors, importers, installers, wholesalers and consumers were included in the interview. The data collected during the interview were then carefully examined and compared with the secondary study.
★Stage 3 ANALYSIS OF THE GATHERED DATA
The analysis team examines and synthesizes the data collected in the first two stages. In order to validate the data, a second round of interviews can be conducted.
★Stage 4 QUANTITATIVE DATA
The quantitative data such as market estimates, production and capacity of manufacturer, market forecasts and investment feasibility is provided by our company. The data is based on the estimates obtained during stage 3.
★Stage 5 QUALITY CONTROL
Before publishing, each report undergoes a rigorous review and editing process, which is done by the experience management team to ensure the reliability of the published data. Every analyst on the research team receives support and continuous training as part of our internal quality process.
1 Study Coverage
1.1 PD-L1 Biomarker Testing Product Introduction
1.2 Market by Type
1.2.1 Global PD-L1 Biomarker Testing Market Size Growth Rate by Type (2020 VS 2024 VS 2031)
1.2.2 PD-L1 (22C3)
1.2.3 PD-L1(28-8)
1.2.4 PD-L1 (SP142)
1.2.5 PD-L1 (SP263)
1.2.6 Other
1.3 Market by Application
1.3.1 Global PD-L1 Biomarker Testing Market Size Growth Rate by Application (2020 VS 2024 VS 2031)
1.3.2 Hospital
1.3.3 Diagnostic Center
1.3.4 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global PD-L1 Biomarker Testing Market Size Estimates and Forecasts
2.2 PD-L1 Biomarker Testing Market Size by Region: 2024 Versus 2031
2.2.1 Global PD-L1 Biomarker Testing Revenue by Region: 2020-2025
2.2.2 Global PD-L1 Biomarker Testing Revenue Forecast by Region (2026-2031)
2.2.3 Global PD-L1 Biomarker Testing Revenue Market Share by Region (2020-2031)
3 Market Segments
3.1 Breakdown Data by Type
3.1.1 Global PD-L1 Biomarker Testing Revenue by Type (2020-2031)
3.1.2 Global PD-L1 Biomarker Testing Revenue Market Share by Type (2020-2031)
3.2 Breakdown Data by Application
3.2.1 Global PD-L1 Biomarker Testing Revenue by Application (2020-2031)
3.2.2 Global PD-L1 Biomarker Testing Revenue Market Share by Application (2020-2031)
3.3 by Type and by Application Crossing Analysis
3.3.1 PD-L1 (22C3) of PD-L1 Biomarker Testing Revenue Market Share by Application
3.3.2 PD-L1(28-8) of PD-L1 Biomarker Testing Revenue Market Share by Application
3.3.3 PD-L1 (SP142) of PD-L1 Biomarker Testing Revenue Market Share by Application
3.3.4 PD-L1 (SP263) of PD-L1 Biomarker Testing Revenue Market Share by Application
3.3.5 Other of PD-L1 Biomarker Testing Revenue Market Share by Application
4 Global PD-L1 Biomarker Testing by Company
4.1 Global PD-L1 Biomarker Testing Revenue by Company (2020-2025)
4.2 Global PD-L1 Biomarker Testing Revenue Share by Company (2020-2025)
4.3 Competitive Landscape
4.3.1 Key PD-L1 Biomarker Testing Companies around the World: Ranking by Revenue
4.3.2 Global PD-L1 Biomarker Testing Market Concentration Ratio (CR5 and HHI) & (2020-2025)
4.3.3 Global PD-L1 Biomarker Testing Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
4.4 Global PD-L1 Biomarker Testing Companies Headquarters & Product Type
4.4.1 Global PD-L1 Biomarker Testing Companies Headquarters
4.4.2 Date of International Companies Enter into PD-L1 Biomarker Testing Market
4.4.3 Global PD-L1 Biomarker Testing Companies Product & Service
4.4.4 PD-L1 (22C3) Revenue Market Share of PD-L1 Biomarker Testing by Company
4.4.5 PD-L1(28-8) Revenue Market Share of PD-L1 Biomarker Testing by Company
4.4.6 PD-L1 (SP142) Revenue Market Share of PD-L1 Biomarker Testing by Company
4.4.7 PD-L1 (SP263) Revenue Market Share of PD-L1 Biomarker Testing by Company
4.4.8 Other Revenue Market Share of PD-L1 Biomarker Testing by Company
4.5 Global PD-L1 Biomarker Testing Mergers & Acquisitions, Expansion Plans
5 Company Profiles
5.1 Agilent Technologies
5.1.1 Agilent Technologies Corporation Information
5.1.2 Agilent Technologies Description, Business Overview
5.1.3 Agilent Technologies PD-L1 Biomarker Testing Products Offered
5.1.4 Agilent Technologies PD-L1 Biomarker Testing Revenue and Gross Margin (2020-2025)
5.1.5 Agilent Technologies PD-L1 Biomarker Testing Revenue by Product in 2024
5.1.6 Agilent Technologies PD-L1 Biomarker Testing Revenue by Application in 2024
5.1.7 Agilent Technologies PD-L1 Biomarker Testing Revenue by Geographic Area in 2024
5.1.8 Agilent Technologies Recent Developments
5.2 Roche
5.2.1 Roche Corporation Information
5.2.2 Roche Description, Business Overview
5.2.3 Roche PD-L1 Biomarker Testing Products Offered
5.2.4 Roche PD-L1 Biomarker Testing Revenue and Gross Margin (2020-2025)
5.2.5 Roche PD-L1 Biomarker Testing Revenue by Product in 2024
5.2.6 Roche PD-L1 Biomarker Testing Revenue by Application in 2024
5.2.7 Roche PD-L1 Biomarker Testing Revenue by Geographic Area in 2024
5.2.8 Roche Recent Developments
5.3 Merck
5.3.1 Merck Corporation Information
5.3.2 Merck Description, Business Overview
5.3.3 Merck PD-L1 Biomarker Testing Products Offered
5.3.4 Merck PD-L1 Biomarker Testing Revenue and Gross Margin (2020-2025)
5.3.5 Merck PD-L1 Biomarker Testing Revenue by Product in 2024
5.3.6 Merck PD-L1 Biomarker Testing Revenue by Application in 2024
5.3.7 Merck PD-L1 Biomarker Testing Revenue by Geographic Area in 2024
5.3.8 Merck Recent Developments
5.4 Bristol-Myers Squibb
5.4.1 Bristol-Myers Squibb Corporation Information
5.4.2 Bristol-Myers Squibb Description, Business Overview
5.4.3 Bristol-Myers Squibb PD-L1 Biomarker Testing Products Offered
5.4.4 Bristol-Myers Squibb PD-L1 Biomarker Testing Revenue and Gross Margin (2020-2025)
5.4.5 Bristol-Myers Squibb PD-L1 Biomarker Testing Revenue by Product in 2024
5.4.6 Bristol-Myers Squibb PD-L1 Biomarker Testing Revenue by Application in 2024
5.4.7 Bristol-Myers Squibb PD-L1 Biomarker Testing Revenue by Geographic Area in 2024
5.4.8 Bristol-Myers Squibb Recent Developments
5.5 AstraZeneca
5.5.1 AstraZeneca Corporation Information
5.5.2 AstraZeneca Description, Business Overview
5.5.3 AstraZeneca PD-L1 Biomarker Testing Products Offered
5.5.4 AstraZeneca PD-L1 Biomarker Testing Revenue and Gross Margin (2020-2025)
5.5.5 AstraZeneca PD-L1 Biomarker Testing Revenue by Product in 2024
5.5.6 AstraZeneca PD-L1 Biomarker Testing Revenue by Application in 2024
5.5.7 AstraZeneca PD-L1 Biomarker Testing Revenue by Geographic Area in 2024
5.5.8 AstraZeneca Recent Developments
5.6 Ono Pharmaceutical
5.6.1 Ono Pharmaceutical Corporation Information
5.6.2 Ono Pharmaceutical Description, Business Overview
5.6.3 Ono Pharmaceutical PD-L1 Biomarker Testing Products Offered
5.6.4 Ono Pharmaceutical PD-L1 Biomarker Testing Revenue and Gross Margin (2020-2025)
5.6.5 Ono Pharmaceutical PD-L1 Biomarker Testing Revenue by Product in 2024
5.6.6 Ono Pharmaceutical PD-L1 Biomarker Testing Revenue by Application in 2024
5.6.7 Ono Pharmaceutical PD-L1 Biomarker Testing Revenue by Geographic Area in 2024
5.6.8 Ono Pharmaceutical Recent Developments
5.7 Regeneron
5.7.1 Regeneron Corporation Information
5.7.2 Regeneron Description, Business Overview
5.7.3 Regeneron PD-L1 Biomarker Testing Products Offered
5.7.4 Regeneron PD-L1 Biomarker Testing Revenue and Gross Margin (2020-2025)
5.7.5 Regeneron PD-L1 Biomarker Testing Revenue by Product in 2024
5.7.6 Regeneron PD-L1 Biomarker Testing Revenue by Application in 2024
5.7.7 Regeneron PD-L1 Biomarker Testing Revenue by Geographic Area in 2024
5.7.8 Regeneron Recent Developments
5.8 Innovent
5.8.1 Innovent Corporation Information
5.8.2 Innovent Description, Business Overview
5.8.3 Innovent PD-L1 Biomarker Testing Products Offered
5.8.4 Innovent PD-L1 Biomarker Testing Revenue and Gross Margin (2020-2025)
5.8.5 Innovent PD-L1 Biomarker Testing Revenue by Product in 2024
5.8.6 Innovent PD-L1 Biomarker Testing Revenue by Application in 2024
5.8.7 Innovent PD-L1 Biomarker Testing Revenue by Geographic Area in 2024
5.8.8 Innovent Recent Developments
5.9 Hengrui Medicine
5.9.1 Hengrui Medicine Corporation Information
5.9.2 Hengrui Medicine Description, Business Overview
5.9.3 Hengrui Medicine PD-L1 Biomarker Testing Products Offered
5.9.4 Hengrui Medicine PD-L1 Biomarker Testing Revenue and Gross Margin (2020-2025)
5.9.5 Hengrui Medicine PD-L1 Biomarker Testing Revenue by Product in 2024
5.9.6 Hengrui Medicine PD-L1 Biomarker Testing Revenue by Application in 2024
5.9.7 Hengrui Medicine PD-L1 Biomarker Testing Revenue by Geographic Area in 2024
5.9.8 Hengrui Medicine Recent Developments
5.10 Junshi Biosciences
5.10.1 Junshi Biosciences Corporation Information
5.10.2 Junshi Biosciences Description, Business Overview
5.10.3 Junshi Biosciences PD-L1 Biomarker Testing Products Offered
5.10.4 Junshi Biosciences PD-L1 Biomarker Testing Revenue and Gross Margin (2020-2025)
5.10.5 Junshi Biosciences PD-L1 Biomarker Testing Revenue by Product in 2024
5.10.6 Junshi Biosciences PD-L1 Biomarker Testing Revenue by Application in 2024
5.10.7 Junshi Biosciences PD-L1 Biomarker Testing Revenue by Geographic Area in 2024
5.10.8 Junshi Biosciences Recent Developments
6 North America
6.1 North America PD-L1 Biomarker Testing Market Size YoY Growth 2020-2031
6.2 North America PD-L1 Biomarker Testing Market Facts & Figures by Country (2020-2031)
6.3 North America PD-L1 Biomarker Testing Revenue by Type (2020-2025)
6.4 North America PD-L1 Biomarker Testing Revenue by Application (2020-2025)
7 Asia-Pacific
7.1 Asia-Pacific PD-L1 Biomarker Testing Market Size YoY Growth 2020-2031
7.2 Asia-Pacific PD-L1 Biomarker Testing Market Facts & Figures by Region (2020-2031)
7.3 Asia-Pacific PD-L1 Biomarker Testing Revenue by Type (2020-2025)
7.4 Asia-Pacific PD-L1 Biomarker Testing Revenue by Application (2020-2025)
8 Europe
8.1 Europe PD-L1 Biomarker Testing Market Size YoY Growth 2020-2031
8.2 Europe PD-L1 Biomarker Testing Market Facts & Figures by Country (2020-2031)
8.3 Europe PD-L1 Biomarker Testing Revenue by Type (2020-2025)
8.4 Europe PD-L1 Biomarker Testing Revenue by Application (2020-2025)
9 Latin America
9.1 Latin America PD-L1 Biomarker Testing Market Size YoY Growth 2020-2031
9.2 Latin America PD-L1 Biomarker Testing Market Facts & Figures by Country (2020-2031)
9.3 Latin America PD-L1 Biomarker Testing Revenue by Type (2020-2025)
9.4 Latin America PD-L1 Biomarker Testing Revenue by Application (2020-2025)
10 Middle East and Africa
10.1 Latin America PD-L1 Biomarker Testing Market Size YoY Growth 2020-2031
10.2 Middle East and Africa PD-L1 Biomarker Testing Market Facts & Figures by Country (2020-2031)
10.3 Middle East and Africa PD-L1 Biomarker Testing Revenue by Type (2020-2025)
10.4 Middle East and Africa PD-L1 Biomarker Testing Revenue by Application (2020-2025)
11 Supply Chain and Sales Channel analysis
11.1 PD-L1 Biomarker Testing Supply Chain Analysis
11.2 PD-L1 Biomarker Testing Key Raw Materials and Upstream Suppliers
11.3 PD-L1 Biomarker Testing Clients Analysis
11.4 PD-L1 Biomarker Testing Sales Channel and Sales Model Analysis
11.4.1 PD-L1 Biomarker Testing Distribution Channel Analysis: Indirect Sales VS Direct Sales
11.4.2 PD-L1 Biomarker Testing Distribution Channel Analysis: Online Sales VS Offline Sales
11.4.3 PD-L1 Biomarker Testing Distributors
12 PD-L1 Biomarker Testing Market Dynamics
12.1 PD-L1 Biomarker Testing Industry Trends
12.2 PD-L1 Biomarker Testing Market Drivers
12.3 PD-L1 Biomarker Testing Market Challenges
12.4 PD-L1 Biomarker Testing Market Restraints
13 Research Findings and Conclusion
14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach
14.1.1.1 Research Programs/Design
14.1.1.2 Market Size Estimation
14.1.1.3 Market Breakdown and Data Triangulation
14.1.2 Data Source
14.1.2.1 Secondary Sources
14.1.2.2 Primary Sources
14.2 Author Details
14.3 Disclaimer
List of Tables
Table 1. Global PD-L1 Biomarker Testing Market Size Growth Rate (CAGR) by Type (US$ Million): 2020 VS 2024 VS 2031
Table 2. Global PD-L1 Biomarker Testing Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
Table 3. Global PD-L1 Biomarker Testing Market Size by Region (US$ Million): 2024 VS 2031
Table 4. Global PD-L1 Biomarker Testing Revenue by Region (2020-2025) & (US$ Million)
Table 5. Global PD-L1 Biomarker Testing Revenue Forecast by Region (2026-2031) & (US$ Million)
Table 6. Global PD-L1 Biomarker Testing Revenue by Type (2020-2025) & (US$ Million)
Table 7. Global PD-L1 Biomarker Testing Revenue Forecast by Type (2026-2031) & (US$ Million)
Table 8. Global PD-L1 Biomarker Testing Revenue by Application (2020-2025) & (US$ Million)
Table 9. Global PD-L1 Biomarker Testing Revenue Forecast by Application (2026-2031) & (US$ Million)
Table 10. PD-L1 Biomarker Testing Revenue by Company (2020-2025) & (US$ Million)
Table 11. PD-L1 Biomarker Testing Revenue Share by Company (2020-2025)
Table 12. Ranking of Global Top PD-L1 Biomarker Testing Players by Revenue (US$ Million) in 2024
Table 13. Global PD-L1 Biomarker Testing Companies Market Concentration Ratio (CR5 and HHI) & (2020-2025)
Table 14. Global PD-L1 Biomarker Testing by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in PD-L1 Biomarker Testing as of 2024)
Table 15. Global PD-L1 Biomarker Testing Companies Headquarters
Table 16. Date of International Companies Enter into PD-L1 Biomarker Testing Market
Table 17. Global PD-L1 Biomarker Testing Companies Product & Service
Table 18. Global PD-L1 Biomarker Testing Mergers & Acquisitions, Expansion Plans
Table 19. Agilent Technologies Corporation Information
Table 20. Agilent Technologies Description and Business Overview
Table 21. Agilent Technologies PD-L1 Biomarker Testing Product
Table 22. Agilent Technologies PD-L1 Biomarker Testing Revenue (US$ Million) and Gross Margin (2020-2025)
Table 23. Agilent Technologies Revenue Proportion of PD-L1 Biomarker Testing by Product in 2024
Table 24. Agilent Technologies Revenue Proportion of PD-L1 Biomarker Testing by Application in 2024
Table 25. Agilent Technologies Revenue Proportion of PD-L1 Biomarker Testing by Geographic Area in 2024
Table 26. Agilent Technologies Recent Developments
Table 27. Roche Corporation Information
Table 28. Roche Description and Business Overview
Table 29. Roche PD-L1 Biomarker Testing Product
Table 30. Roche PD-L1 Biomarker Testing Revenue (US$ Million) and Gross Margin (2020-2025)
Table 31. Roche Revenue Proportion of PD-L1 Biomarker Testing by Product in 2024
Table 32. Roche Revenue Proportion of PD-L1 Biomarker Testing by Application in 2024
Table 33. Roche Revenue Proportion of PD-L1 Biomarker Testing by Geographic Area in 2024
Table 34. Roche Recent Developments
Table 35. Merck Corporation Information
Table 36. Merck Description and Business Overview
Table 37. Merck PD-L1 Biomarker Testing Product
Table 38. Merck PD-L1 Biomarker Testing Revenue (US$ Million) and Gross Margin (2020-2025)
Table 39. Merck Revenue Proportion of PD-L1 Biomarker Testing by Product in 2024
Table 40. Merck Revenue Proportion of PD-L1 Biomarker Testing by Application in 2024
Table 41. Merck Revenue Proportion of PD-L1 Biomarker Testing by Geographic Area in 2024
Table 42. Merck Recent Developments
Table 43. Bristol-Myers Squibb Corporation Information
Table 44. Bristol-Myers Squibb Description and Business Overview
Table 45. Bristol-Myers Squibb PD-L1 Biomarker Testing Product
Table 46. Bristol-Myers Squibb PD-L1 Biomarker Testing Revenue (US$ Million) and Gross Margin (2020-2025)
Table 47. Bristol-Myers Squibb Revenue Proportion of PD-L1 Biomarker Testing by Product in 2024
Table 48. Bristol-Myers Squibb Revenue Proportion of PD-L1 Biomarker Testing by Application in 2024
Table 49. Bristol-Myers Squibb Revenue Proportion of PD-L1 Biomarker Testing by Geographic Area in 2024
Table 50. Bristol-Myers Squibb Recent Developments
Table 51. AstraZeneca Corporation Information
Table 52. AstraZeneca Description and Business Overview
Table 53. AstraZeneca PD-L1 Biomarker Testing Product
Table 54. AstraZeneca PD-L1 Biomarker Testing Revenue (US$ Million) and Gross Margin (2020-2025)
Table 55. AstraZeneca Revenue Proportion of PD-L1 Biomarker Testing by Product in 2024
Table 56. AstraZeneca Revenue Proportion of PD-L1 Biomarker Testing by Application in 2024
Table 57. AstraZeneca Revenue Proportion of PD-L1 Biomarker Testing by Geographic Area in 2024
Table 58. AstraZeneca Recent Developments
Table 59. Ono Pharmaceutical Corporation Information
Table 60. Ono Pharmaceutical Description and Business Overview
Table 61. Ono Pharmaceutical PD-L1 Biomarker Testing Product
Table 62. Ono Pharmaceutical PD-L1 Biomarker Testing Revenue (US$ Million) and Gross Margin (2020-2025)
Table 63. Ono Pharmaceutical Revenue Proportion of PD-L1 Biomarker Testing by Product in 2024
Table 64. Ono Pharmaceutical Revenue Proportion of PD-L1 Biomarker Testing by Application in 2024
Table 65. Ono Pharmaceutical Revenue Proportion of PD-L1 Biomarker Testing by Geographic Area in 2024
Table 66. Ono Pharmaceutical Recent Developments
Table 67. Regeneron Corporation Information
Table 68. Regeneron Description and Business Overview
Table 69. Regeneron PD-L1 Biomarker Testing Product
Table 70. Regeneron PD-L1 Biomarker Testing Revenue (US$ Million) and Gross Margin (2020-2025)
Table 71. Regeneron Revenue Proportion of PD-L1 Biomarker Testing by Product in 2024
Table 72. Regeneron Revenue Proportion of PD-L1 Biomarker Testing by Application in 2024
Table 73. Regeneron Revenue Proportion of PD-L1 Biomarker Testing by Geographic Area in 2024
Table 74. Regeneron Recent Developments
Table 75. Innovent Corporation Information
Table 76. Innovent Description and Business Overview
Table 77. Innovent PD-L1 Biomarker Testing Product
Table 78. Innovent PD-L1 Biomarker Testing Revenue (US$ Million) and Gross Margin (2020-2025)
Table 79. Innovent Revenue Proportion of PD-L1 Biomarker Testing by Product in 2024
Table 80. Innovent Revenue Proportion of PD-L1 Biomarker Testing by Application in 2024
Table 81. Innovent Revenue Proportion of PD-L1 Biomarker Testing by Geographic Area in 2024
Table 82. Innovent Recent Developments
Table 83. Hengrui Medicine Corporation Information
Table 84. Hengrui Medicine Description and Business Overview
Table 85. Hengrui Medicine PD-L1 Biomarker Testing Product
Table 86. Hengrui Medicine PD-L1 Biomarker Testing Revenue (US$ Million) and Gross Margin (2020-2025)
Table 87. Hengrui Medicine Revenue Proportion of PD-L1 Biomarker Testing by Product in 2024
Table 88. Hengrui Medicine Revenue Proportion of PD-L1 Biomarker Testing by Application in 2024
Table 89. Hengrui Medicine Revenue Proportion of PD-L1 Biomarker Testing by Geographic Area in 2024
Table 90. Hengrui Medicine Recent Developments
Table 91. Junshi Biosciences Corporation Information
Table 92. Junshi Biosciences Description and Business Overview
Table 93. Junshi Biosciences PD-L1 Biomarker Testing Product
Table 94. Junshi Biosciences PD-L1 Biomarker Testing Revenue (US$ Million) and Gross Margin (2020-2025)
Table 95. Junshi Biosciences Revenue Proportion of PD-L1 Biomarker Testing by Product in 2024
Table 96. Junshi Biosciences Revenue Proportion of PD-L1 Biomarker Testing by Application in 2024
Table 97. Junshi Biosciences Revenue Proportion of PD-L1 Biomarker Testing by Geographic Area in 2024
Table 98. Junshi Biosciences Recent Developments
Table 99. North America PD-L1 Biomarker Testing Revenue by Country (2020-2025) & (US$ Million)
Table 100. North America PD-L1 Biomarker Testing Revenue by Country (2026-2031) & (US$ Million)
Table 101. North America PD-L1 Biomarker Testing Revenue by Type (2020-2025) & (US$ Million)
Table 102. North America PD-L1 Biomarker Testing Revenue by Application (2020-2025) & (US$ Million)
Table 103. Asia-Pacific PD-L1 Biomarker Testing Revenue by Region (2020-2025) & (US$ Million)
Table 104. Asia-Pacific PD-L1 Biomarker Testing Revenue by Region (2026-2031) & (US$ Million)
Table 105. Asia-Pacific PD-L1 Biomarker Testing Revenue by Type (2020-2025) & (US$ Million)
Table 106. Asia-Pacific PD-L1 Biomarker Testing Revenue by Application (2020-2025) & (US$ Million)
Table 107. Europe PD-L1 Biomarker Testing Revenue by Country (2020-2025) & (US$ Million)
Table 108. Europe PD-L1 Biomarker Testing Revenue by Country (2026-2031) & (US$ Million)
Table 109. Europe PD-L1 Biomarker Testing Revenue by Type (2020-2025) & (US$ Million)
Table 110. Europe PD-L1 Biomarker Testing Revenue by Application (2020-2025) & (US$ Million)
Table 111. Latin America PD-L1 Biomarker Testing Revenue by Country (2020-2025) & (US$ Million)
Table 112. Latin America PD-L1 Biomarker Testing Revenue by Country (2026-2031) & (US$ Million)
Table 113. Latin America PD-L1 Biomarker Testing Revenue by Type (2020-2025) & (US$ Million)
Table 114. Latin America PD-L1 Biomarker Testing Revenue by Application (2020-2025) & (US$ Million)
Table 115. Middle East and Africa PD-L1 Biomarker Testing Revenue by Country (2020-2025) & (US$ Million)
Table 116. Middle East and Africa PD-L1 Biomarker Testing Revenue by Country (2026-2031) & (US$ Million)
Table 117. Middle East and Africa PD-L1 Biomarker Testing Revenue by Type (2020-2025) & (US$ Million)
Table 118. Middle East and Africa PD-L1 Biomarker Testing Revenue by Application (2020-2025) & (US$ Million)
Table 119. PD-L1 Biomarker Testing Key Raw Materials, Industry Status and Trend
Table 120. PD-L1 Biomarker Testing Key Raw Materials and Upstream Suppliers
Table 121. PD-L1 Biomarker Testing Clients Status and Trend
Table 122. PD-L1 Biomarker Testing Typical Clients
Table 123. PD-L1 Biomarker Testing Distributors
Table 124. PD-L1 Biomarker Testing Market Trends
Table 125. PD-L1 Biomarker Testing Market Drivers
Table 126. PD-L1 Biomarker Testing Market Challenges
Table 127. PD-L1 Biomarker Testing Market Restraints
Table 128. Research Programs/Design for This Report
Table 129. Key Data Information from Secondary Sources
Table 130. Key Data Information from Primary Sources
List of Figures
Figure 1. PD-L1 Biomarker Testing Product Picture
Figure 2. Global PD-L1 Biomarker Testing Market Size by Type (US$ Million): 2020 VS 2024 VS 2031
Figure 3. Global PD-L1 Biomarker Testing Revenue Market Share by Type in 2024 & 2031
Figure 4. PD-L1 (22C3) Product Picture
Figure 5. PD-L1(28-8) Product Picture
Figure 6. PD-L1 (SP142) Product Picture
Figure 7. PD-L1 (SP263) Product Picture
Figure 8. Other Product Picture
Figure 9. Global PD-L1 Biomarker Testing Market Size by Application (US$ Million): 2020 VS 2024 VS 2031
Figure 10. Global PD-L1 Biomarker Testing Revenue Market Share by Application in 2024 & 2031
Figure 11. Hospital
Figure 12. Diagnostic Center
Figure 13. Others
Figure 14. PD-L1 Biomarker Testing Report Years Considered
Figure 15. Global PD-L1 Biomarker Testing Revenue, (US$ Million), 2020 VS 2024 VS 2031
Figure 16. Global PD-L1 Biomarker Testing Market Size (2020-2031) & (US$ Million)
Figure 17. Global PD-L1 Biomarker Testing Market Size Market Share by Region: 2024 Versus 2031
Figure 18. Global PD-L1 Biomarker Testing Revenue Market Share by Region (2020-2031)
Figure 19. Global PD-L1 Biomarker Testing Revenue Market Share Forecast by Type (2020-2031)
Figure 20. Global PD-L1 Biomarker Testing Revenue Market Share Forecast by Application (2020-2031)
Figure 21. PD-L1 (22C3) of PD-L1 Biomarker Testing Revenue Market Share by Application, 2024 VS 2031
Figure 22. PD-L1(28-8) of PD-L1 Biomarker Testing Revenue Market Share by Application, 2024 VS 2031
Figure 23. PD-L1 (SP142) of PD-L1 Biomarker Testing Revenue Market Share by Application, 2024 VS 2031
Figure 24. PD-L1 (SP263) of PD-L1 Biomarker Testing Revenue Market Share by Application, 2024 VS 2031
Figure 25. Other of PD-L1 Biomarker Testing Revenue Market Share by Application, 2024 VS 2031
Figure 26. PD-L1 Biomarker Testing Revenue Share by Company (2024)
Figure 27. PD-L1 Biomarker Testing Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
Figure 28. PD-L1 (22C3) Revenue Proportion by Company in 2024
Figure 29. PD-L1(28-8) Revenue Proportion by Company in 2024
Figure 30. PD-L1 (SP142) Revenue Proportion by Company in 2024
Figure 31. PD-L1 (SP263) Revenue Proportion by Company in 2024
Figure 32. Other Revenue Proportion by Company in 2024
Figure 33. North America PD-L1 Biomarker Testing Revenue 2020-2031 (US$ Million)
Figure 34. North America PD-L1 Biomarker Testing Revenue Market Share by Type (2020-2025)
Figure 35. North America PD-L1 Biomarker Testing Revenue Market Share by Application (2020-2025)
Figure 36. Asia-Pacific PD-L1 Biomarker Testing Revenue 2020-2031 (US$ Million)
Figure 37. Asia-Pacific PD-L1 Biomarker Testing Revenue Market Share by Region (2020-2031)
Figure 38. Asia-Pacific PD-L1 Biomarker Testing Revenue Market Share by Type (2020-2025)
Figure 39. Asia-Pacific PD-L1 Biomarker Testing Revenue Market Share by Application (2020-2025)
Figure 40. Europe PD-L1 Biomarker Testing Revenue Growth Rate 2020-2031 (US$ Million)
Figure 41. Europe PD-L1 Biomarker Testing Revenue Market Share by Country (2020-2031)
Figure 42. Europe PD-L1 Biomarker Testing Revenue Market Share by Type (2020-2025)
Figure 43. Europe PD-L1 Biomarker Testing Revenue Market Share by Application (2020-2025)
Figure 44. Latin America PD-L1 Biomarker Testing Revenue Growth Rate 2020-2031 (US$ Million)
Figure 45. Latin America PD-L1 Biomarker Testing Revenue Market Share by Country (2020-2031)
Figure 46. Latin America PD-L1 Biomarker Testing Revenue Market Share by Type (2020-2025)
Figure 47. Latin America PD-L1 Biomarker Testing Revenue Market Share by Application (2020-2025)
Figure 48. Middle East and Africa PD-L1 Biomarker Testing Revenue Growth Rate 2020-2031 (US$ Million)
Figure 49. Middle East and Africa PD-L1 Biomarker Testing Revenue Market Share by Country (2020-2031)
Figure 50. Middle East and Africa PD-L1 Biomarker Testing Revenue Market Share by Type (2020-2025)
Figure 51. Middle East and Africa PD-L1 Biomarker Testing Revenue Market Share by Application (2020-2025)
Figure 52. PD-L1 Biomarker Testing Supply Chain (Upstream and Downstream Market)
Figure 53. Global Production Market Share of PD-L1 Biomarker Testing Raw Materials by Region in 2024
Figure 54. PD-L1 Biomarker Testing Distribution Channels
Figure 55. Global PD-L1 Biomarker Testing Percentage 2020-2031: Indirect Sales VS Direct Sales
Figure 56. Global PD-L1 Biomarker Testing Percentage 2020-2031: Online Sales VS Offline Sales
Figure 57. Bottom-up and Top-down Approaches for This Report
Figure 58. Data Triangulation
Figure 59. Key Executives Interviewed
